Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/05/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.89% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.83M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 485707 | Beta 0.97 | 52 Weeks Range 1.03 - 3.59 | Updated Date 11/13/2024 |
52 Weeks Range 1.03 - 3.59 | Updated Date 11/13/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.81% | Return on Equity (TTM) -63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12830152 | Price to Sales(TTM) - |
Enterprise Value 12830152 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 13945600 | Shares Floating 13972210 |
Shares Outstanding 13945600 | Shares Floating 13972210 | ||
Percent Insiders 4.07 | Percent Institutions 9.72 |
Analyst Ratings
Rating 5 | Target Price 5.25 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides, Inc. was founded in 2003. It is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its nanoviricide platform technology. The company has primarily focused on preclinical research and development with limited commercial products.
Core Business Areas
- Nanoviricide Platform: Development and application of nanoviricides, which are designed to mimic virus receptors to bind and neutralize viruses.
- Drug Development: Research and development of antiviral drugs targeting various viral diseases, including herpes simplex virus (HSV), influenza, HIV, and coronaviruses.
Leadership and Structure
Dr. Anil Diwan is the Executive Chairman, President, and CEO. The company has a small management team and operates with a research-focused organizational structure.
Top Products and Market Share
Key Offerings
- Herpes Simplex Virus (HSV) Program: NanoViricides' lead program focuses on developing treatments for HSV. This is still in preclinical/clinical stages with no marketed product yet. Competitors include major pharmaceutical companies with established antiviral drugs like acyclovir (GSK), valacyclovir (GSK), and famciclovir (Novartis).
- COVID-19 Program: Development of nanoviricides targeting SARS-CoV-2, the virus that causes COVID-19. Still in preclinical stages. Competitors include Pfizer (Paxlovid), Merck (Molnupiravir), and other vaccine and antiviral drug developers.
Market Dynamics
Industry Overview
The antiviral drug market is large and growing, driven by the emergence of new viral diseases and the increasing prevalence of existing ones. The market is competitive, with major pharmaceutical companies holding significant market share.
Positioning
NanoViricides is a niche player focused on innovative nanomedicine approaches to antiviral therapy. Its competitive advantage lies in its proprietary nanoviricide platform, which it believes can overcome limitations of existing antiviral drugs.
Total Addressable Market (TAM)
The global antiviral drugs market is estimated to be worth hundreds of billions of US dollars and is expected to grow further in the future. NanoViricides is positioned to capture a small but potentially significant share of this market if its products are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary nanoviricide platform technology
- Potential for broad-spectrum antiviral activity
- Focus on unmet medical needs in antiviral therapy
Weaknesses
- Limited financial resources
- Reliance on preclinical and early-stage clinical data
- Lack of approved products and revenue
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for antiviral research
- Expanding into new viral disease targets
- Breakthrough Therapy designations or other expedited regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval timelines
- Patent challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- MRK
- PFE
- JNJ
- ABBV
Competitive Landscape
NanoViricides faces significant competition from established pharmaceutical companies with greater resources and experience in drug development and commercialization. Its nanoviricide platform represents a potential competitive advantage, but it needs to demonstrate clinical efficacy and safety to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the company's early stage of development and lack of commercialized products.
Future Projections: Future growth depends on successful development and commercialization of its nanoviricide-based therapies. Analyst estimates vary widely due to the high risk associated with drug development.
Recent Initiatives: Focusing on advancing its HSV and COVID-19 programs. Seeking partnerships and funding to support clinical development.
Summary
NanoViricides Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company. Its nanoviricide platform technology holds promise, but it faces significant challenges in securing funding, navigating regulatory hurdles, and competing with established pharmaceutical companies. The company's success hinges on the successful development and commercialization of its antiviral therapies.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.